A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of LY4065967, to Evaluate the Effect of LY4065967 on the Pharmacokinetics of Rosuvastatin, and to Assess Regional Absorption of LY4065967 in Healthy Japanese Participants
Latest Information Update: 26 Sep 2024
At a glance
- Drugs LY 4065967 (Primary) ; Rosuvastatin
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eli Lilly and Company
- 26 Sep 2024 New trial record